Molly Woods
Psychiatric/Mental Health · Kansas City, KSNPI 1710661228
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 409 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,975, 3.6 times the $816 reported in 2023. Among psychiatric/mental health clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $14.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$741
- Alkermes, Inc.$721
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$715
- AbbVie$714
- Neurocrine Biosciences, Inc.$644
- E.r. Squibb & Sons, L.L.C.$478
- plus $2K from 10 others
What the payments were for
- Food & beverage$5,907100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 48 | $741 |
| Alkermes, Inc. | 39 | $721 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $715 |
| AbbVie | 63 | $714 |
| Neurocrine Biosciences, Inc. | 33 | $644 |
| E.r. Squibb & Sons, L.L.C. | 39 | $478 |
| Teva Pharmaceuticals USA, Inc. | 47 | $453 |
| Axsome Therapeutics, Inc. | 26 | $393 |
| Johnson & Johnson | 14 | $315 |
| Vanda Pharmaceuticals Inc. | 31 | $275 |
| Lundbeck LLC | 9 | $186 |
| Indivior Inc. | 8 | $159 |
| Noven Therapeutics, LLC | 3 | $49 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Braeburn Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
How this compares
$5,907 in reported general payments places this provider in the 90th percentile of 404 psychiatric/mental health providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 21 | $166,387 |
| Abilify MaintenaAripiprazole | 39 | $118,855 |
| Invega SustennaPaliperidone Palmitate | 34 | $111,164 |
| AristadaAripiprazole Lauroxil | 19 | $62,288 |
| PerserisRisperidone | 13 | $40,700 |
| RexultiBrexpiprazole | 23 | $32,879 |
| VraylarCariprazine Hcl | 14 | $19,461 |
| BelsomraSuvorexant | 26 | $11,993 |
| Aripiprazole | 120 | $10,108 |
| FetzimaLevomilnacipran Hcl | 11 | $5,715 |
| Quetiapine Fumarate | 123 | $3,188 |
| Vilazodone Hcl | 19 | $2,182 |
| Trazodone Hcl | 203 | $2,089 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 49 | $1,855 |
| Ramelteon | 12 | $1,532 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $644 | $166,38721 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $741 | $151,73462 claims |
| Johnson & JohnsonInvega Sustenna | $315 | $111,16434 claims |
| Alkermes, Inc.Aristada | $721 | $62,28819 claims |
| Indivior Inc.Perseris | $159 | $40,70013 claims |
| AbbVieVraylar, Fetzima | $714 | $25,17625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 404 psychiatric/mental health providers in Kansas.
Other psychiatric/mental health in Kansas City
- Louise MuhoziKansas City$14K
- Sarah KassinKansas City$5K
- Eric ThomasonPittsburg$333K
- Belinda BagbyHutchinson$39K
- Hayley KnappWichita$31K
- Jennifer KubinBaldwin City$26K
- Uyen DinhPittsburg$20K
- Theresa MuellerOverland Park$14K
- Shiney ZchariaOlathe$14K
- Deborah MurphyWichita$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.